Immunity Against Measles in Korean Autologous Hematopoietic Stem Cell Transplant Recipients

• DOI: 10.3346/jkms.2024.39.e224
• Publication Date: 2024-07-08T05:48:50Z
• Authors: Hyeon Mu Jang; Seongman Bae; Jiwon Jung; Hyungwoo Cho; Dok Hyun Yoon; Sung-Han Kim
• Keywords: Male; Adult; Measles Vaccine; Hematopoietic Stem Cell Transplantation; Middle Aged; Brief Communication; Antibodies, Viral; Transplantation, Autologous; Measles virus; Immunoglobulin G; Republic of Korea; Humans; Female; Measles

The seropositivity of measles antibodies among 261 autologous stem cell transplant recipients (ASCTs) in Korea, assessed approximately 1-2 years after transplant (median, 11 months; interquartile range, 9-14), was significantly lower than age- and sex-matched control healthcare workers (83.1% [217/261] vs. 90.3% [539/597], P = 0.002). The findings underscore the vulnerability of adult ASCT recipients to measles. Clinicians should prioritize testing for measles IgG after ASCT and consider vaccination for ASCT recipients who remain seronegative 2 years after ASCT.